A global perspective on the epidemiology of pulmonary hypertension

Canadian Journal of Cardiology

Volumn 31, Issue 4, 2015, Pages 375-381

  Mocumbi, Ana Olga ^a,b   Thienemann, Friedrich ^c   Sliwa, Karen ^c,d  

^a INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

^b EDUARDO MONDLANE UNIVERSITY   (Mozambique)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; BRAIN NATRIURETIC PEPTIDE; CARBON MONOXIDE; PYRROLIZIDINE ALKALOID; TRYPTOPHAN;

AFRICA SOUTH OF THE SAHARA; AIR POLLUTION; ALTITUDE; CARDIOMYOPATHY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; COMBUSTION; COMORBIDITY; DEVELOPING COUNTRY; DIASTOLIC DYSFUNCTION; EISENMENGER COMPLEX; ENVIRONMENTAL CHANGE; ENVIRONMENTAL FACTOR; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HEART DISEASE; HEART INDEX; HEART MUSCLE FIBROSIS; HEART RIGHT ATRIUM PRESSURE; HEREDITY; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MINING; MITRAL VALVE DISEASE; MORTALITY; PREVALENCE; PROGNOSIS; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; RHEUMATIC HEART DISEASE; RISK FACTOR; SCHISTOSOMIASIS; SICKLE CELL ANEMIA; SOCIOECONOMICS; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TRADITIONAL MEDICINE;

EID: 84964303775     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2015.01.030     Document Type: Review

References (91)

1. Bogaard H.J., Abe K., Noordegraaf A.V., Voelkel N.F. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009, 135:794-804.
2. Laurent S., Vanhoutte P., Cavero I., et al. The arterial wall: a new pharmaceutical and therapeutic target. Fundam Clin Pharmacol 1996, 10:243-257.
3. Hoeper M.M., Bogaard H.J., Condliffe M.R., et al. Definitions and diagnosis of pulmonary hypertension. JAm Coll Cardiol 2013, 62:D42-D50.
4. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. JAm Coll Cardiol 2002, 40:780-788.
5. Ryan J.J., Thenappan T., Luo N., et al. The WHO classification of pulmonary hypertension: A case-based imaging compendium. Pulm Circ 2012, 2:107-121.
6. Hatano S., Strasser T. Primary Pulmonary Hypertension 1975, World Health Organization, Geneva.
7. Kovacs G., Berghold A., Scheidl S., Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects. A systematic review. Eur Respir J 2009, 34:888-894.
8. Badesch B.D., Champion H.C., Gomez-Sanchez M.A., et al. Diagnosis and assessment of pulmonary arterial hypertension. JAm Coll Cardiol 2009, 54:S55-S56.
9. Galie N., Hoeper M.M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30:2493-2537.
10. Hoeper M.M., Bogaard H.J., Condliffe R., et al. Definitions and diagnosis of pulmonary hypertension. JAm Coll Cardiol 2013, 62:D42-50.
11. Oudiz R.J. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med 2007, 28:233-241.
12. Fisher M., Forfia P., Chamera E., Housten-Harris T., et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009, 179:615-621.
13. Thienemann F., Dzudie A., Mocumbi A.O., et al. Rationale and design of the Pan African Pulmonary hypertension Cohort (PAPUCO) study: implementing a contemporary registry on pulmonary hypertension in Africa. BMJ Open 2014, 4:e005950.
14. Berger M., Haimowitz A., Van Tosh A., Berdoff R.L., Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. JAm Coll Cardiol 1985, 6:359-365.
15. Currie P.J., Seward J.B., Chan K.L., et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. JAm Coll Cardiol 1985, 6:750-756.
16. Fisher M.R., Criner G.J., Fishman A.P., et al. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J 2007, 30:914-921.
17. Arcasoy S.M., Christie J.D., Ferrari V.A., et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003, 167:735-740.
18. Humbert M., Sitbon O., Chaouat A., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006, 173:1023-1030.
19. Hyduk A., Croft J.B., Ayala C., et al. Pulmonary hypertension surveillance-United States, 1980-2002. MMWR Surveill Summ 2005, 54:1-28.
20. Strange G., Playford D., Stewart S., et al. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart 2012, 98:1805-1811.
21. Lam C.S., Borlaug B.A., Kane G.C., et al. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation 2009, 119:2663-2670.
22. Satoh T. Current practice for pulmonary hypertension. Chin Med J 2014, 127:3491-3495.
23. Humbert M., Sitbon O., Yaïci A., et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010, 36:549-555. French Pulmonary Arterial Hypertension Network.
24. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987, 107:216-223.
25. McGoon M.D., Benza R.L., Escribano-Subias P., et al. Pulmonary arterial hypertension: epidemiology and registries. JAm Coll Cardiol 2013, 62(25 suppl):D51-D59.
26. Jing Z.C., Xu X.Q., Han Z.Y., et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 2007, 132:373-379.
27. Marin M.J., Rotes A.S., Ogando A.R., et al. Assessing pulmonary hypertensive vascular disease in childhood. Data from the Spanish registry. Am J Respir Crit Care Med 2014, 190:1421-1429. REPIHED Investigators.
28. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
29. Ogawa A., Ejiri K., Matsubara H. Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. Life Sci 2014, 118:414-419.
30. Barst R.J., Ivy D.D., Foreman A.J., McGoon M.D., Rosenzweilg E.B. Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry). Am J Cardiol 2014, 113:147-155.
31. Lam C.S.P., Donal E., Kraigher-Krainer E., Vasan R.S. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011, 13:18-28.
32. Sliwa K., Davison B., Mayosi B., et al. Readmission and death after an acute heart failure event: predictors and outcomes in sub-Saharan Africa: results from the THESUS-HF registry. Eur Heart J 2013, 34:3151-3159.
33. Penaloza D., Arias-Stella J. The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness. Circulation 2007, 115:1132-1146.
34. Graham B.B., Bandeira A.P., Morrel N.W., Butrous G., Tuder R.M. Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest 2010, 137(6 suppl):20S-29S.
35. Mocumbi A.O., Lameira E., Yaksh A., et al. Challenges on the management of congenital heart disease in developing countries. Int J Cardiol 2011, 148:285-288.
36. Sani M., Mukhtar-Yola M., Karaye K. Spectrum of congenital heart disease in a tropical environment: an echocardiographic study. JNatl Med Assoc 2007, 99:665-669.
37. Lopes A.A., Barst R.J., Haworth S.G., et al. Repair of congenital heart disease with associated pulmonary hypertension in children: what are the minimal investigative procedures? Consensus statement from the Congenital Heart Disease and Pediatric Task Forces, Pulmonary Vascular Research Institute (PVRI). Pulm Circ 2014, 4:330-341.
38. Serjeant G.R. The case for dedicated sickle cell centers. Ind J Hum Genet 2006, 12:148-151.
39. World Health Organization. Global distribution of haemoglobin disorders, interms of births of affected infants per 1000 births. Accessed March 4, 2015. http://www.who.int/genomics/public/Maphaemoglobin.pdf.
40. Aliyu Z., Kato G., Taylor J., et al. Sickle cell disease and pulmonary hypertension in Africa: a global perspective and review of epidemiology, pathophysiology, and management. Am J. Hematol 2008, 83:63-70.
41. Sutton L.L., Castro O., Cross D.J., et al. Pulmonary hypertension in sickle cell disease. Am J Cardiol 1994, 74:626-628.
42. Powars D., Weidman J.A., Odom-Maryon T., Niland J.C., Johnson C. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine 1988, 67:66-76.
43. Gladwin M.T., Kato G.J. Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia. Nat Med 2002, 8:1383-1389.
44. Peters M., Plaat B.E., ten Cate H., et al. Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost 1994, 71:169-172.
45. Hagger D., Wolff S., Owen J., Samson D. Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls. Blood Coagul Fibrinolysis 1995, 6:93-99.
46. Morris C.R., Kuypers F.A., Larkin S., Vichinsky E.P., Styles L.A. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. JPediatr Hematol Oncol 2000, 22:515-520.
47. Machado R.F. Sickle cell anemia-associated pulmonary arterial hypertension. JBras Pneumol 2007, 33:583-591.
48. Chitsulo L., Engels D., Montresor A., Savioli L. The global status of schistosomiasis and its control. Acta Trop 2000, 77:41-51.
49. Papamatheakis D.G., Mocumbi A.O., Kim N.H., Mandel J. Schistosomiasis-associated pulmonary hypertension. Pulm Circ 2014, 4:596-611.
50. Ferreira R.C., Domingues A.L., Bandeira A.P., et al. Prevalence of pulmonary hypertension in patients with schistosomal liver fibrosis. Ann Trop Med Parasitol 2009, 103:129-143.
51. Lapa M., Dias B., Jardim C., et al. Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation 2009, 119:1518-1523.
52. Gonçalves E.C., Fonseca A.P., Pittella J.E. Frequency of schistosomiasis mansoni, of its clinicopathological forms and of the ectopic locations of the parasite in autopsies in Belo Horizonte, Brazil. JTrop Med Hyg 1995, 98:289-295.
53. Kim K.K., Factor S.M. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol 1987, 18:1293-1296.
54. Petrosillo N., Chinello P., Cicalini S. Pulmonary hypertension in individuals with HIV infection. AIDS 2006, 20:2128-2129.
55. Thienemann F., Sliwa K., Rockstroh J. HIV and the heart: the impact of antiretroviral therapy: a global perspective. Eur Heart J 2013, 34:3538-3546.
56. Opravil M., Pechere M., Speich R., et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997, 155:990-995.
57. Petitpretz P., Brenot F., Azarian R., et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994, 89:2722-2727.
58. Sitbon O., Lascoux-Combe C., Delfraissy J.F., et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008, 177:108-113.
59. Degano B., Yaici A., Le Pavec J., et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009, 33:92-98.
60. Quezada M., Martin-Carbonero L., Soriano V., et al. Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up. AIDS 2012, 26:1387-1392.
61. Nunes H., Humbert M., Sitbon O., et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003, 167:1433-1439.
62. Degano B., Guillaume M., Savale L., et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 2010, 24:67-75.
63. Guazzi M., Galie N. Pulmonary hypertension in left heart disease. Eur Respir Rev 2012, 21(126):338-346.
64. Lam C.S., Roger V.L., Rodeheffer R.J., et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. JAm Coll Cardiol 2009, 53:1119-1126.
65. Leung C.C., Moondra V., Catherwood E., et al. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol 2010, 106:284-286.
66. Guazzi M., Borlaug B.A. Pulmonary hypertension due to left heart disease. Circulation 2012, 126:975-990.
67. Zühlke L, Engel M, Karthikeyan G, etal. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (The REMEDY study) [e-pub ahead of print]. Eur Heart J 2014 Nov25. accessed March 4, 2015. http://dx.doi.org/10.1093/eurheartj/ehu449.
68. Nogueira P.R., Rassi S., Correia K.S. Epidemiological, clinical and therapeutic profile of heart failure in a tertiary hospital. Arq Bras Cardiol 2010, 95:392-398.
69. Thenappan T., Gomberg-Maitland M. Epidemiology of pulmonary hypertension and right ventricular failure in left heart failure. Curr Heart Fail Rep 2014, 11:428-435.
70. Dzudie A., Kengue A., Thienemann F., Sliwa K. Predictors of hospitalisations for heart failure and mortality in patients with pulmonary hypertension associated with left heart disease: a systematic review. BMJ Open 2014, 4:e004843.
71. Sofowora E. Pulmonary heart disease in Ibadan. Thorax 1971, 26:339-342.
72. Okowobi B.O. Pattern of heart failure at Lagos-University Hospital. WAfr Med J 1967, 16:198-203.
73. Steenekamp J.H., Simson I.W., Theron W. Cardiovascular causes of death at Tshepong Hospital in 1 year, 1989-1990: a necropsy study. SAfr Med J 1992, 81:142-146.
74. Stewart S., Mocumbi A.O., Carrington M.J., et al. Anot-so-rare form of heart failure in urban black Africans: pathways to right heart failure in the Heart of Soweto Study cohort. Eur J Heart Fail 2011, 13:1070-1077.
75. Torbicki A., Perrier A., Konstantinides S., et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008, 29:2276-2315.
76. Lang I.M. Chronic thromboembolic pulmonary hypertension-not so rare after all. NEngl J Med 2004, 350:2236-2238.
77. Rubin L.J., Hoeper M.M., Klepetko W., et al. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. Proc Am Thorac Soc 2006, 3:601-607.
78. Fedullo P.F., Auger W.R., Kerr K.M., Rubin L.J. Chronic thromboembolic pulmonary hypertension. NEngl J Med 2001, 345:1465-1472.
79. Jamieson S.W., Kapelanski D.P. Pulmonary endarterectomy. Curr Probl Surg 2000, 37:165-252.
80. Moser K.M., Auger W.R., Fedullo P.F. Chronic major-vessel thromboembolic pulmonary hypertension. Circulation 1990, 81:1735-1743.
81. Ribeiro A., Lindmarker P., Johnsson H., Juhlin-Dannfelt A., Jorfeldt L. Pulmonary embolism: one-year follow-up with echocardiography Doppler and five-year survival analysis. Circulation 1999, 99:1325-1330.
82. Pengo V., Lensing A.W., Prins M.H., et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. NEngl J Med 2004, 350:2257-2264.
83. Mocumbi A.O. Right ventricular endomyocardial fibrosis (2013 Grover Conference series). Pulm Circ 2014, 4:363-369.
84. Zelikoff J.T., Chen L.C., Cohen M.D., Schlesinger R.B. The toxicology of inhaled woodsmoke. JToxicol Environ Health B Crit Rev 2002, 5:269-282.
85. Moran-Mendoza O., Perz-Padilla R., Salazar-Flores M., Vazquez-Alfaro F. Wood smoke-associated lung disease: a clinical, functional, radiological and pathological description. Int J Tuber Lung Dis 2008, 12:1092-1098.
86. Sandoval J., Salas J., Martinez-Guerra M.L., et al. Pulmonary arterial hypertension and cor pulmonale associated with chronic domestic wood-smoke inhalation. Chest 1993, 103:12-20.
87. Heath D., Shaba J., Williams A., Smith P., Kombe A. Apulmonary hypertension-producing plant from Tanzania. Thorax 1975, 30:399-404.
88. Kay J.M., Harris P., Heath D. Pulmonary hypertension produced in rats by ingestion of Crotalaria spectabilis seeds. Thorax 1967, 22:176-179.
89. Kay J.M. Dietary pulmonary hypertension. Thorax 1994, 49:S33-S38.
90. James T.N. The toxic oil syndrome. Clin Cardiol 1994, 17:463-470.
91. Simonneau G., Gatzoulis M.A., Adatia I., et al. Updated clinical classification of pulmonary hypertension. JAm Coll Cardiol 2013, 62(25 suppl):D34-41.